The role of dopamine for the pathophysiology of schizophrenia

International Review of Psychiatry

Volumn 19, Issue 4, 2007, Pages 337-345

  Meisenzahl, E M ^a   Schmitt, G J ^a   Scheuerecker, J ^a   Moller H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GLUTAMIC ACID; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; RADIOLIGAND;

COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MOTIVATION; NEUROIMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; REVIEW; REWARD; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; WORKING MEMORY;

BRAIN; CORPUS STRIATUM; DOPAMINE; HUMANS; NEURONS; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34547645771     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701502468     Document Type: Review

References (83)

1. Abler, B., Erk, S., & Walter, H. (2007). Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology, 191, 823-33.
2. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M. et al. (1998). Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort. American Journal of Psychiatry, 155, 761-767.
3. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., & Kegeles, L. S., et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 97(14), 8104-9.
4. Bannon, M. J., Sacchetti, P., & Granneman, J. G. (2000). The dopamine transporter: potential involvement in neuropsychiatric disorders. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology. the fourth generation of progress, , Online Edition (pp. 134-138). New York: Raven Press.
5. Bannon, M. J., Michelhaugh, S. K., Wang, J., & Sacchetti, P. (2001). The human dopamine transporter gene: Gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 11, 449-55.
6. Baracskay, K. L., Haroutunian, V., & Meador-Woodruff, J. H. (2006). Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. 60(4), 271-9.
7. Berridge, K. C. (1996). Food reward: Brain substrates of wanting and liking. Neuroscience and Biobehavioral Reviews, 20, 1-25.
8. Bonci, A., Grillner, P., Siniscalchi, A., Mercuri, N. B., & Bernardi, G. (1997). Glutamate metabotropic receptor agonists depress excitatory and inhibitory transmission on rat mesencephalic principal neurons. The European Journal of Neuroscience, 9, 2359-2369.
9. Breier, A., Su, T. P., Saunders, R., Carson, R. E., Kolachana, B. S., & de Bartolomeis, A., et al., (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America, 94(6), 2569-74.
10. Buchsbaum, M. S., Christian, B. T., Lehrer, D. S., Narayanan, T. K., Shi, B., Mantil, J. et al. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research, 85, 232-244.
11. Bustillo, J., Barrow, R., Paz, R., Tang, J., Seraji-Bozorgzad, N., Moore, G. J. et al. (2006). Long-term treatment of rats with haloperidol: Lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology, 31, 751-756.
12. Carlsson, A., Waters, N., Waters, S., & Carlsson, M. L. (2000). Network interactions in schizophrenia - therapeutic implications. Brain Research Brain Research Reviews, 31, 342-349.
13. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annual Review of Pharmacology and Toxicology, 41, 237-60.
14. Chan, P., Langston, J. W., & Di Monte, D. A. (1993). MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. The. Journal of Pharmacology and Experimental Therapeutics, 267, 1515-20.
15. Christian, B. T., Lehrer, D. S., Shi, B., Narayanan, T. K., Strohmeyer, P. S., Buchsbaum, M. S. et al. (2006). Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage, 31, 139-152.
16. Ciliax, B. J., Heilman, C., Demechyshyn, L. L., Pristupa, Z. B., Ince, E., Hersch, S. M. et al. (1995). The dopamine transporter: Immunochemical characterization and localization in brain. The Journal of neuroscience: The official journal of the Society for Neuroscience, 15, 1714-23.
17. Cragg, S. J., & Rice, M. E. (2004). Dancing past the DAT at a DA synapse. Trends in Neurosciences, 27, 270-277.
18. Dao-Castellana, M. H., Paillere-Martinot, M. L., Hantraye, P., Attar-Levy, D., Remy, P., Crouzel, C. et al. (1997). Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research, 23, 167-74.
19. De Haan, L., Lavalaye, J., van Bruggen, M., van Nimwegen, L., Booij, J., van Amelsvoort, T. et al. (2004). Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: Clinical implications. Canadian Journal of Psychiatry, 49, 290-296.
20. De Haan, L., Lavalaye, J., Booij, J., & Linszen, D. (2005). Comfort, self-confidence, safety, and dopamine D2 receptor occupancy by antipsychotics. American Journal of Psychiatry, 162, 1544-1545.
21. Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., & Straub, R. E., et al., (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 98(12), 6917-22.
22. El-Ghundi, M., O'Dowd, B. F., & George, S. R. (2007). Insights into the role of dopamine receptor systems in learning and memory. Reviews in the neurosciences, 18, 37-66.
23. Ferry, A. T., Ongur, D., An, X., & Price, J. L. (2000). Prefrontal cortical projections to the striatum in macaque monkeys: Evidence for an organization related to prefrontal networks. The Journal of Comparative Neurology, 425, 447-470.
24. Glenthoj, B. Y., Mackeprang, T., Svarer, C., Rasmussen, H., Pinborg, L. H., Friberg, L. et al. (2006). Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry, 60, 621-629.
25. Goldman-Rakic, P. S. (1996). Regional and cellular fractionation of working memory. Proceedings of the National Academy of Sciences of the United States of America, 93(24), 13473-80.
26. Grace, A. A. (2000). Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research Brain Research Reviews, 31, 330-341.
27. Grace, A. A. (2001). Psychostimulant action on dopamine and limbic system function: Relevance to the pathophysiology and treatment of ADHD. In M. V. Solanto, A. F. T. Arnsten & F. X. Castellanos (Eds.), Stimulant drugs and ADHD: Basic and clinical neuroscience (pp. 134-157). New York: Oxford University Press.
28. Grace, A. A. Dopamine (2002). K. L. Davis, D. Charney & C. Nemeroff (Eds.), Neuropsychopharmacology. The Fifth Generation of Progress. An Official Publication of the American College of Neuropsychopharmacology (pp. 120-132). Philadelphia: Lippincott Williams & Wilkins.
29. Grace, A. A., & Bunney, B. S. (1984). The control of firing pattern in nigral dopamine neurons: Burst firing. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 4, 2877-2890.
30. Grillner, P., Bonci, A., Svensson, T. H., Bernardi, G., & Mercuri, N. B. (1999). Presynaptic muscarinic (M3) receptors reduce excitatory transmission in dopamine neurons of the rat mesencephalon. Neuroscience, 91, 557-565.
31. Grillner, P., Berretta, N., Bernardi, G., Svensson, T. H., & Mercuri, N. B. (2000). Muscarinic receptors depress GABAergic synaptic transmission in rat midbrain dopamine neurons. Neuroscience, 96, 299-307.
32. Guillin, O., Abi-Dargham, A., & Laruelle, M. (2007). Neurobiology of Dopamine in Schizophrenia. International Review of Neurobiology, 78, 1-41.
33. Harte, M. K., Bachus, S. B., & Reynolds, G. P. (2005). Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophrenia Research, 75, 303-308.
34. Heinz, A., Siessmeier, T., Wrase, J., Hermann, D., Klein, S., Grässer, S. M. et al. (2004). Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. American Journal of Psychiatry, 161, 1783-9.
35. Hietala, J., Syvälahti, E., Vuorio, K., Räkköläinen, V., Bergman, J., Haaparanta, M. et al. (1995). Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet, 346, 1130-1.
36. Hsiao, M. C., Lin, K. J., Liu, C. Y., Tzen, K. Y., & Yen, T. C. (2003). Dopamine transporter change in drug-naive schizophrenia: An imaging study with 99mTc-TRODAT-1. Schizophrenia Research, 65, 39-46.
37. Joel, D., & Weiner, I. (2000). The connections of the dopaminergic system with the striatum in rats and primates: An analysis with respect to the functional and compartmental organization of the striatum. Neuroscience, 96, 451-474.
38. Juckel, G., Schlagenhauf, F., Koslowski, M., Filonov, D., Wüstenberg, T., Villringer, A. et al. (2006a). Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology, 187, 222-228.
39. Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B. et al. (2006). Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage, 29, 409-416.
40. Kienast, T., & Heinz, A. (2006). Dopamine and the diseased brain. CNS & Neurological Disorders Drug Targets, 5, 109-31.
41. Knutson, B., Adams, C. M., Fong, G. W., & Hommer, D. (2001). Anticipation of increasing monetary reward selectively recruits nucleus accumbens. Journal of Neurosciences, 21, RC159.
42. Koh, P. O., Bergson, C., Undie, A. S., Goldman-Rakic, P. S., & Lidow, M. S. (2003). Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Archives of General Psychiatry, 60, 311-9.
43. Koob, G. F., & Le Moal, M. (1997). Drug abuse: Hedonic homeostatic dysregulation. Science, 278, 52-8.
44. Krawczyk, D. C., Gazzaley, A., & Desposito, M. (2007). Reward modulation of prefrontal and visual association cortex during an incentive working memory task. Brain Research, 13, 1141, 168-77.
45. Laakso, A., Vilkman, H., Alakare, B., Haaparanta, M., Bergman, J., Solin, O. et al. (2000). Striatal Dopamine Transporter Binding in Neuroleptic-Naive Patients with Schizophrenia Studied with Positron Emission Tomography. American Journal of Psychiatry, 157, 269-271.
46. Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., & Erdos, J., et al., (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America, 93, 9235-9240.
47. Laruelle, M., D'Souza, C. D., Baldwin, R. M., Abi-Dargham, A., Kanes, S. J., Fingado, C. L. et al. (1997). Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology, 17, 162-74.
48. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999). Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biological Psychiatry, 46, 56-72.
49. Laruelle, M., Abi-Dargham, A., van Dyck, C., Gil, R., DáSouza, D. C., Krystal, J. et al. (2000). Dopamine and Serotonin Transporters in Patients with Schizophrenia: An Imaging Study with [123I]β-CIT. Biological Psychiatry, 47, 371-379.
50. Lavalaye, J., Linszen, D. H., Booij, J., Dingemans, P. M. A. J., Reneman, L., Habraken, J. B.A et al. (2001). Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophrenia Research, 47, 59-67.
51. Lindstrom, L. H., Gefvert, O., Hagberg, G., Lundberg, T., Bergstrom, M., Hartvig, P. et al. (1999). Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biological Psychiatry, 46, 681-8.
52. Lindquist, D. M., Hawk, R. M., Karson, C. N., & Komoroski, R. A. (2000). Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine, 43, 355-358.
53. Meador-Woodruff, J. H., Damask, S. P., Wang, J., Haroutunian, V., Davis, K. L., & Watson, S. J. (1996). Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology, 15, 17-29.
54. Meisenzahl, E. M., Dresel, S., Frodl, T., Schmitt, G. J., Preuss, U. W., Rossmuller, B. et al. (2000). D2 receptor occupancy under recommended and high doses of olanzapine: An iodine-123-iodobenzamide SPECT study. Journal of Psychopharmacology, 14, 364-70.
55. Meisenzahl, E. M., Scheuerecker, J., Zipse, M., Ufer, S., Wiesmann, M., Frodl, T. et al. (2006). Effects of treatment with the atypical neuroleptic quetiapine on working memory function: A functional MRI follow-up investigation. European Archives of Psychiatry and Clinical Neurosciences, 256, 522-31.
56. Mercuri, N. B., Grillner, P., & Bernardie, G. (1996). N-methyl-D-aspartate receptors mediate a slow excitatory postsynaptic potential in the rat midbrain dopaminergic neurons. Neuroscience, 74, 785-792.
57. Mizrahi, R., Rusjan, P., Agid, O., Graff, A., Mamo, D. C., Zipursky, R. B. et al. (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extra-striatal D2 receptors: A PET study in schizophrenia. American Journal of Psychiatry, 164, 630-637.
58. Mueller, U., von Cramon, D. Y., & Pollmann, S. (1998). D1-versus D2-receptor modulation of visuospatial working memory in humans. Journal of Neurosciences, 8, 2720-8.
59. Pilowsky, L. S., Costa, D. C., Ell, P. J., Verhoeff, N. P., Murray, R. M., & Kervin, R. W. (1994). Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. British Journal of Psychiatry, 163, 833-4, Erratum in: British Journal of Psychiatry, 1994 Feb; 164:270.
60. Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., & Andermann, F., et al., (1994). Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proceedings of the National Academy of Sciences of the United States of America, 91 (24), 11651-4.
61. Rujescu, D., Bender, A., Keck, M., Hartmann, A. M., Ohl, F., Raeder, H. et al. (2006). A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional and behavioral abnormalities. Biological Psychiatry, 59, 721-9.
62. Rowland, L., Bustillo, J. R., & Lauriello, J. (2001). Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Seminars in Clinical Neuropsychiatry, 6, 121-130.
63. Richfield, E. K., Penney, J. B., & Young, A. B. (1989). Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience, 30, 767-777.
64. Schmitt, G. J. E., Frodl, T., Tatsch, K., Dresel, S., Möller, H-J., & Meisenzahl, E. M. (2000). Striatal dopamine transporter in drug-naive schizophrenic patients: A 99mTc-TRODAT-1-SPECT-Study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 10(Suppl 3), 324.
65. Schmitt, G. J. E., Frodl, T., Dresel, S., Möller, H-J., & Meisenzahl, E. M. (2001). Striatal Dopaminergic Synapses in Drug Naive Schizophrenics. The World Journal of Biological psycHiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 2(Supplement 1), 93S.
66. 99mTc]TRODAT-1. Journal of Psychopharmacology, 19, 488-93.
67. Schmitt, G. J. E., Frodl, T., Dresel, S., la Fougère, C., Bottlender, R., Koutsouleris, N. et al. (2006). Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. European Archives of Psychiatry and Clinical Neurosciences, 256, 115-121.
68. 123I]IBZM SPECT. Psychiatry Research: Neuroimaging (in revision).
69. Schmitt, G. J. E., la Fougère, C., Dresel, S., Frodl, T., Hahn, K., & Möller, H-J., et al., (2007). Dual-isotope SPECT imaging of striatal dopamine in first-episode, drug naïve schizophrenic patients. Schizophrenia Research (submitted).
70. High states, implying many path to psychosis. Proceedings of the National Academy of Sciences of the United States of America, 102, 3513-3518.
71. 2 receptor in schizophrenia. Expert opinion on therapeutic targets, 10, 515-531.
72. Sesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., & Levey, A. I. (1998). Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. Journal of Neurosciencs, 18, 2697-2708.
73. Smolders, I., De Klippel, N., Sarre, S., Ebinger, G., & Michotte, Y. (1995). Tonic GABAergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. European Journal of Pharmacology, 284, 83-91.
74. 2 Receptor Binding in the Anterior Cingulate Cortex in Schizophrenia. Archives of General Psychiatry, 59, 25-30.
75. Takahashi, H., Kato, M., Hayashi, M., Okubo, Y., Takano, A., Ito, H. et al. (2007). Memory and frontal lobe functions: Possible relations with dopamine D2 receptors in the hippocampus. Neuroimage, 34, 1643-1649.
76. Tuppurainen, H., Kuikka, J., Vilnamäki, H., Husso-Saastamoinen, M., Bergström, K., & Tiihonen, J. (2003). Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naïve schizophrenic patients. Molecular Psychiatry, 8, 453-455.
77. Vollenweider, F. X., & Geyer, M. A. (2001). A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Research Bulletin, 56, 495-507.
78. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R. et al. (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature, 24;386, 830-3.
79. Waelti, P., Dickinson, A., & Schultz, W. (2001). Dopamine responses comply with basic assumptions of formal learning theory. Nature, 412, 43-8.
80. Wise, R. A. (1996). Neurobiology of addiction. Current Opinion in Neurobiology, 6, 243-51.
81. Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry, 44, 660-9.
82. Wolf, M. E., Dahlin, S. L., Hu, X. T., Xue, C. J., & White, K. (1995). Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioural sensitization to amphetamine: Comparison with N-methyl-D-aspartate antagonists. Neuroscience, 69, 417-439.
83. Yang, Y. K., Yu, L., Yeh, L. Y., Chiu, N. T., Chen, P. S., & Lee, I. H. (2004). Associated Alterations of Striatal Dopamine D2/D3 Receptor and Transporter Binding in Drug-Naïve Patients With Schizophrenia: A Dual-Isotope SPECT Study. American Journal of Psychiatry, 161, 1496-1498.